Acorda Therapeutics took a calculated risk in 2014 when it bought Civitas Therapeutics in a bid to start accumulating drugs for Parkinson’s disease. But that deal has a chance to soon pay off for the Ardsley, NY, company.
Acorda (NASDAQ: ACOR... Read more »
The blowback from U.S. business leaders to President Trump’s travel ban continues—today from a throng of biotech executives. This morning, 165 U.S. biotech leaders have signed a letter voicing “deep concern and opposition” to the order, which bars entry to the... Read more »
President Trump’s order to bar refugees and immigrants from seven Muslim-majority countries is on temporary hold, and a court hearing later today could eventually force a ruling by the U.S. Supreme Court.
One of the latest biotech executives to speak out... Read more »
The deal-making and investment in New England’s enterprise IT sector continues.
Today, Stratoscale announced its acquisition of Cambridge, MA-based Tesora, a database-as-a-service provider.
Deal terms weren’t disclosed, but the purchase price probably wasn’t huge. Herzliya, Israel-based Stratoscale has raised about $70... Read more »
Folks had just clocked out last Friday when the Trump Administration announced a travel ban that threw airports around the country into chaos. That announcement set the tone for this week in life sciences. Many in biopharma blasted Trump’s order and... Read more »
Amgen revealed on Thursday that its cholesterol lowering drug, evolocumab (Repatha)—part of a new class of heart treatments called PCSK9 inhibitors—has reduced the risk of heart attacks and strokes in a massive, 27,500 patient trial.
Thousand Oaks, CA-based Amgen (NASDAQ: AMGN... Read more »
A team of decorated academic chemists in San Diego have been working since 2014 on a biotech startup that aims to find new drugs faster. The company now has a lot of cash in the bank and a well-known biopharma scientist... Read more »
[Updated, 1:57 pm E.T., see below] Another major U.S. health insurer, UnitedHealthCare, has said it would cover the first-ever approved drug for the rare disease spinal muscular atrophy, a closely watched bellwether in the national debate over drug prices.... Read more »
Royalty Pharma, a New York-based company that buys up rights to royalty streams of potentially revenue-producing drugs, is paying $90 million for a for a chance to reap 4.5 percent royalty on possible sales of an experimental heart drug being... Read more »